BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37858287)

  • 1. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
    Liu M; Bunn V; Hupf B; Lin J; Lin J
    Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
    Zhang W; Pan Z; Yuan Y
    J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulating and reporting frequentist operating characteristics of clinical trials that borrow external information: Towards a fair comparison in case of one-arm and hybrid control two-arm trials.
    Kopp-Schneider A; Wiesenfarth M; Held L; Calderazzo S
    Pharm Stat; 2024; 23(1):4-19. PubMed ID: 37632266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
    Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
    Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
    Jin H; Kim MO; Scheffler A; Jiang F
    Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian clinical trial design using historical data that inform the treatment effect.
    Psioda MA; Ibrahim JG
    Biostatistics; 2019 Jul; 20(3):400-415. PubMed ID: 29547966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
    Harari O; Soltanifar M; Verhoek A; Heeg B
    Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating historical control information in ANCOVA models using the meta-analytic-predictive approach.
    Qi H; Rizopoulos D; van Rosmalen J
    Res Synth Methods; 2022 Nov; 13(6):681-696. PubMed ID: 35439840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.